A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated <it>Plasmodium falciparum </it>malaria in eastern Sudan
<p>Abstract</p> <p>Background</p> <p>Artemisinin-based combination therapy is increasingly being adopted as first-line antimalarial therapy. The choice of appropriate therapy depends on efficacy, cost, side effects, and simplicity of administration.</p> <p>M...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , |
|---|---|
| Formáid: | LEABHAR |
| Foilsithe / Cruthaithe: |
BMC,
2006-08-01T00:00:00Z.
|
| Ábhair: | |
| Rochtain ar líne: | Connect to this object online. |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
| Achoimre: | <p>Abstract</p> <p>Background</p> <p>Artemisinin-based combination therapy is increasingly being adopted as first-line antimalarial therapy. The choice of appropriate therapy depends on efficacy, cost, side effects, and simplicity of administration.</p> <p>Methods</p> <p>the efficacy of fixed co-formulated (f) artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at time intervals of 12 hours for a 24-hour therapy was compared with the efficacy of the same drug given as a loose combination (AS+SMP l) with a dose interval of 24 hours for 3 days for the treatment of uncomplicated <it>Plasmodium falciparum </it>malaria in eastern Sudan.</p> <p>Results</p> <p>seventy-three patients (39 and 34 in the fixed and the loose regimen of AS+SMP respectively) completed the 28-days of follow-up. On day 3; all patients in both groups were a parasitaemic but one patient in the fixed group of AS+SMP f was still febrile.</p> <p>Polymerase chain reaction genotyping adjusted cure rates on day 28 were 92.3% and 97.1% (<it>P </it>> 0.05) for the fixed and loose combination of AS+SMP respectively.</p> <p>Three (4.1%) patients (one in the fixed and two patients in the loose group of AS+SMP) in the study suffered drug-related adverse effects.</p> <p>Gametocytaemia was not detected during follow-up in any of the patients.</p> <p>Conclusion</p> <p>both regimens of AS+SMP were effective and safe for the treatment of uncomplicated <it>P. falciparum </it>malaria in eastern Sudan. Due to its simplicity, the fixed dose one-day treatment regimen may improve compliance and therefore may be the preferred choice.</p> |
|---|---|
| Cur síos ar an mír: | 10.1186/1476-0711-5-18 1476-0711 |